Insurers’ decisions about which services to cover are often based on economic models that are seemingly objective but neglect factors affecting people who are economically disadvantaged.
AMA J Ethics. 2021;23(8):E648-652. doi:
10.1001/amajethics.2021.648.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Camillo Lamanna, MMathPhil, MBBS and Lauren Byrne, MBBS
Perhaps machine learning systems trained on patients’ electronic health records and social media footprints could be used as decision aids when patients lack capacity or face overwhelming decisions.
AMA J Ethics. 2018;20(9):E902-910. doi:
10.1001/amajethics.2018.902.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Global health outreach programs can risk benefitting students from resource-rich areas of the world more than the patients in resource-poor areas of the world. This month’s episode of Ethics Talk explores an alternative to academic health center-based health outreach programs.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.